212 related articles for article (PubMed ID: 18078012)
1. Are pleiotropic effects of statins real?
Corsini A; Ferri N; Cortellaro M
Vasc Health Risk Manag; 2007; 3(5):611-3. PubMed ID: 18078012
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
3. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
Bisgaier CL; Essenburg AD; Auerbach BJ; Pape ME; Sekerke CS; Gee A; Wölle S; Newton RS
J Lipid Res; 1997 Dec; 38(12):2502-15. PubMed ID: 9458274
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
6. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin: pharmacological characteristics and lipid-lowering effects.
Poli A
Drugs; 2007; 67 Suppl 1():3-15. PubMed ID: 17910517
[TBL] [Abstract][Full Text] [Related]
9. Direct vascular effects of HMG-CoA reductase inhibitors.
Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
[TBL] [Abstract][Full Text] [Related]
10. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
11. The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins.
Murphy C; Deplazes E; Cranfield CG; Garcia A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228116
[TBL] [Abstract][Full Text] [Related]
12. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
13. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic vascular protective effects of statins in perioperative medicine.
Fang SY; Roan JN; Luo CY; Tsai YC; Lam CF
Acta Anaesthesiol Taiwan; 2013 Sep; 51(3):120-6. PubMed ID: 24148741
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of sterol synthesis by the monoterpene perillyl alcohol is unaffected by competitive 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.
Cerda SR; Wilkinson J; Branch SK; Broitman SA
Lipids; 1999 Jun; 34(6):605-15. PubMed ID: 10405975
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Kumai T; Matsumoto N; Koitabashi Y; Takeba Y; Oonuma S; Sekine S; Tadokoro M; Kobayashi S
Curr Med Chem Cardiovasc Hematol Agents; 2005 Jul; 3(3):195-201. PubMed ID: 15974884
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition.
Kettunen J; Holmes MV; Allara E; Anufrieva O; Ohukainen P; Oliver-Williams C; Wang Q; Tillin T; Hughes AD; Kähönen M; Lehtimäki T; Viikari J; Raitakari OT; Salomaa V; Järvelin MR; Perola M; Davey Smith G; Chaturvedi N; Danesh J; Di Angelantonio E; Butterworth AS; Ala-Korpela M
PLoS Biol; 2019 Dec; 17(12):e3000572. PubMed ID: 31860674
[TBL] [Abstract][Full Text] [Related]
18. HMG-CoA Reductase as Target for Drug Development.
Gunasekaran B; Shukor MY
Methods Mol Biol; 2020; 2089():245-250. PubMed ID: 31773659
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
20. The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway.
Scharnagl H; Schliack M; Löser R; Nauck M; Gierens H; Jeck N; Wieland H; Gross W; März W
Atherosclerosis; 2000 Nov; 153(1):69-80. PubMed ID: 11058701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
